An Update on Anti-thrombotic Therapy Following Transcatheter Aortic Valve Implantation: Expert Cardiologist Opinion from a UK and Ireland Delphi Group.

Autor:	Zaman A; Department of Cardiology, Freeman Hospital Newcastle upon Tyne, UK.; Newcastle University Newcastle upon Tyne, UK., Prendergast B; Department of Cardiology, St Thomas' Hospital London, UK.; Cleveland Clinic London, UK., Hildick-Smith D; Sussex Cardiac Centre, Regional Specialist Unit, Brighton and Sussex University Hospitals Brighton, UK., Blackman D; Department of Cardiology, Leeds Teaching Hospitals NHS Trust Leeds, UK., Anderson R; Department of Cardiology, University Hospital of Wales Cardiff, UK.; Cardiff Metropolitan University Cardiff, UK., Spence MS; Department of Cardiology Mater Private Hospital Dublin, Ireland., Mylotte D; Department of Cardiology, University Hospitals Galway Galway, Ireland.; National University of Galway Galway, Ireland., Smith D; Department of Cardiology, Morriston Hospital Swansea, UK.; University of Swansea Swansea, UK., Wilding B; Health Economics and Outcomes Research Cardiff, UK., Chapman C; Bristol Myers Squibb Pharmaceuticals Uxbridge, Middlesex, UK., Atkins K; Bristol Myers Squibb Pharmaceuticals Uxbridge, Middlesex, UK., Pollock KG; Bristol Myers Squibb Pharmaceuticals Uxbridge, Middlesex, UK., Qureshi AC; Bristol Myers Squibb Pharmaceuticals Princeton, NJ, US., Banning A; Department of Cardiology, John Radcliffe Hospital Oxford, UK.
Jazyk:	angličtina
Zdroj:	Interventional cardiology (London, England) [Interv Cardiol] 2023 Apr 10; Vol. 18, pp. e13. Date of Electronic Publication: 2023 Apr 10 (Print Publication: 2023).
DOI:	10.15420/icr.2022.11
Abstrakt:	Transcatheter aortic valve implantation (TAVI) is an effective and established treatment for symptomatic aortic stenosis. However, there is a lack of consensus concerning the need for peri- and post-procedural anti-thrombotic medication. Contemporary guidelines recommend that anti-thrombotic therapy is balanced against a patient's bleeding risk following TAVI, but do not fully consider the evolving evidence base. The purpose of the Delphi panel recommendations presented here is to provide a consensus elicited from a panel of experts who regularly prescribe anti-thrombotic therapy post-TAVI. The goal was to address evidence gaps across four key topics: anti-thrombotic therapy (anti-platelet and/or anti-coagulant) in TAVI patients in sinus rhythm; anti-thrombotic therapy in TAVI patients with AF; direct oral anti-coagulants versus vitamin K antagonists; and the need for UK/Ireland specific guidance. This consensus statement aims to inform clinical decision-making by providing a concise, evidence-based summary of best practice for prescribing anti-thrombotic therapies following TAVI and highlights areas where further research is needed. Competing Interests: Disclosure: ACQ, CC, KA, and KGP are employees of Bristol Myers Squibb (BMS). AZ and AB received funding from BMS for advisory support throughout this study. AZ has received consulting fees from BMS, AstraZeneca, Boehringer and Pfizer, and speaker/educational honoraria from BMS, Pfizer and Boehringer. BP has received educational/research grants from Edwards Lifesciences, consulting fees from Microport, lecture fees from Edwards Lifesciences, Medtronic, Abbott and Anteris, and advisory/safety monitoring board participation for Colibri and Anteris. RA has received speaker/educational honoraria from Shockwave and safety monitoring board participation for the ARCH study. MSS has received consulting fees from Edwards Lifesciences, Gore, Abbott, Medtronic and Boston Scientific, speaker/educational honoraria from BMS, and support for meeting attendance/travel from EuroPCR. DM has received grants, consulting fees and speaker/educational honoraria from Medtronic, Boston Scientific and Microport, support for meeting attendance/travel from Medtronic and Boston Scientific, and advisory board participation for Medtronic. All other authors have no conflicts of interest to declare. Funding: The study was sponsored by Pfizer and BMS. (Copyright © 2023, Radcliffe Cardiology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu